The company said revenue for Q4 2024 rose 45% to $13.53 billion, and reported EPS rose 102% to $4.88. It cited higher sales volumes of Mounjaro and Zepbound as the driver of revenue growth.

1. 01

   The company said revenue for Q4 2024 rose 45% to $13.53 billion, and reported EPS rose 102% to $4.88. It cited higher sales volumes of Mounjaro and Zepbound as the driver of revenue growth.

2. 02

   Eli Lilly said revenue growth of 45% for Q4 reflected a 48% increase in volume, partly offset by a 4% decrease due to lower realized prices. It also said Jardiance revenue included a one-time $300.0 million benefit tied to an amendment to its collaboration with Boehringer Ingelheim.

3. 03

   The company said its reported gross margin for Q4 2024 rose to 82.2%, up 1.3 percentage points. Acquired IPR&D charges were $189.2 million in the same quarter, compared with $622.6 million a year earlier, and asset impairment, restructuring and other special charges were $344.0 million, mainly including an intangible asset impairment for Vitrakvi.

4. 04

   The company said it expects revenue for 2025 to be between $58.0 billion and $61.0 billion, reported EPS between $22.05 and $23.55, and non-GAAP EPS between $22.50 and $24.00. It estimated its effective tax rate at approximately 16%.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.